Osorio-Olivares, M; Rezende, MC; Sepúlveda-Boza, S; Cassels, BK; Fierro, A. MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the β-position. Bioorg. Med. Chem., 1 Jan 2004, 12 (15), 4055–4066. 412 kB. https://doi.org/10.1016/j.bmc.2004.05.033 #18 MS,NMR
Glennon, RA; Liebowitz, SM. Serotonin receptor affinity of cathinone and related analogues. J. Med. Chem., 1 Jan 1982, 25 (4), 393–397. 665 kB. https://doi.org/10.1021/jm00346a012 MS,NMR
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #46
Pedersen, AJ; Reitzel, LA; Johansen, SS; Linnet, K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test. Anal., 1 Jun 2013, 5 (6), 430-438. 378 kB. https://doi.org/10.1002/dta.1369
Mayer, FP; Cintulova, D; Pittrich, DA; Wimmer, L; Luethi, D; Holy, M; Jaentsch, K; Tischberger, S; Gmeiner, G; Hoener, MC; Liechti, ME; Mihovilovic, MD; Sitte, HH. Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. Neuropharmacology, 1 Apr 2019, 148, 199-209. 1.4 MB. https://doi.org/10.1016/j.neuropharm.2018.12.032 #nor-Mephedrone
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #P24 LC